CFS 2017

Cabozantinib or Nivolumab Plus Ipilimumab as Treatment Options for Renal Cell Carcinoma

Cabozantinib or Nivolumab Plus Ipilimumab as Treatment Options for Renal Cell Carcinoma

By

A review of data from the CABOSUN and CheckMate-214 trials to determine the use of targeted therapy in metastatic renal cell carcinoma.

Ribociclib Plus Letrozole Prolongs PFS in Advanced Breast Cancer: A Secondary Analysis of MONALEESA-2

Ribociclib Plus Letrozole Prolongs PFS in Advanced Breast Cancer: A Secondary Analysis of MONALEESA-2

By

Although endocrine therapy has been the standard of care for HR+/HER2- breast cancer, cyclin-D and cyclin-dependent kinase (CDK) dysregulation-driven resistance to this treatment occurs at very high rates among patients.

Liquid Biopsies: An Emerging, Effective, Versatile Monitoring Modality in Lung Cancer

Liquid Biopsies: An Emerging, Effective, Versatile Monitoring Modality in Lung Cancer

By

In lung cancer, it is critical to evaluate the resistance mechanisms so appropriate treatment can be administered.

First-line Osimertinib for <i>EGFR</i>-mutation Positive NSCLC

First-line Osimertinib for EGFR-mutation Positive NSCLC

By

The discovery of molecular biomarkers and EGFR mutations have shifted the management of NSCLC from traditional cytotoxic chemotherapies towards precision medicine with TKIs.

The Role of Anti-PD-1 Immunotherapy in Advanced Triple-negative Breast Cancer

The Role of Anti-PD-1 Immunotherapy in Advanced Triple-negative Breast Cancer

By

Breast cancer was previously thought to not be immunogenic in nature, but a subset of patients with breast cancer, primarily with triple negative disease, have exhibited robust levels of tumor infiltrating leukocytes.

Nivolumab Provides Long-term Benefit after Auto-HCT Classical Hodgkin Lymphoma

Nivolumab Provides Long-term Benefit after Auto-HCT Classical Hodgkin Lymphoma

By

An interim analysis of a cohort in the CheckMate-205 study showed that nivolumab had an acceptable safety profile and demonstrated efficacy among patients with relapsed and refractory classical Hodgkin lymphoma after post-auto-HCT brentuximab vedotin.

Survival Predictors in Ovarian Cancer and Current Immunotherapeutic Strategies

Survival Predictors in Ovarian Cancer and Current Immunotherapeutic Strategies

By

Researchers have found 3 major predictors for survival: tumor infiltrating leukocytes (TIL), programmed death-ligand 1 (PD-L1) expression, and mutational burden.

Current and Future Roles of PARP Inhibitors in Ovarian Cancer

Current and Future Roles of PARP Inhibitors in Ovarian Cancer

By

Ovarian cancer risk is known to be increased by BRCA1 and BRCA2 gene mutations, but recent developments have led researchers to believe there are several genes involved in homologous recombination-mediated DNA damage.

Studies That May Shift Treatment Paradigms in Gastric Cancer: A Review of Recent Trials

Studies That May Shift Treatment Paradigms in Gastric Cancer: A Review of Recent Trials

By

In 2017, new treatment approaches for patients with esophagogastric cancer have been investigated, including novel neoadjuvant regimens and immunotherapies.

Patient Clinical Features Should Be Sequentially Considered to Determine Optimal Treatment in CLL

Patient Clinical Features Should Be Sequentially Considered to Determine Optimal Treatment in CLL

By

In order to optimize therapeutic sequencing among patients with CLL, 5 patient aspects must be considered.

Elotuzumab May Provide Greatest Sustained Relative PFS Benefit in Multiple Myeloma

Elotuzumab May Provide Greatest Sustained Relative PFS Benefit in Multiple Myeloma

By

Four recently approved treatment regimens have demonstrated a PFS benefit for patients with RRMM relative to Rd, but no head-to-head studies have been conducted.

Melatonin Analogues May Have Antitumor Properties in Melanoma and Breast Cancer

Melatonin Analogues May Have Antitumor Properties in Melanoma and Breast Cancer

By

Previous studies have demonstrated that melatonin and its analogues, in addition to their ability to regulate circadian rhythms, may exhibit cytotoxic activity via various cellular mechanisms.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs